Latest from Perlmutter Cancer Center at NYU Langone

Marc J. Braunstein, MD, PhD, discusses transplant eligibility in multiple myeloma.

From implementing telemedical approaches to resequencing treatments, cancer centers across the nation have nimbly adapted to face the clinical challenges posed by the novel coronavirus 2019 disease.

Anna C. Pavlick, DO, discusses sequencing challenges faced in the treatment of patients with BRAF-mutant melanoma.

Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses how to judiciously use steroids to manage adverse events in patients with melanoma who are receiving immunotherapy.

Scott T. Tagawa, MD, MS, discusses remaining questions regarding treatment selection and PSMA imaging in metastatic castration-resistant prostate cancer.

Mohammad Maher Abdul Hay, MD, discusses the process of evaluating the eligibility of patients with acute lymphoblastic leukemia for transplant.

 Shella Saint Fleur-Lominy, MD, PhD, discusses the use of ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms.
 

Michael L. Grossbard, MD, discusses the role of minimal residual disease in follicular lymphoma.